Welcome to our dedicated page for Imunon SEC filings (Ticker: IMNN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Imunon, Inc. (IMNN) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as a Nasdaq Capital Market issuer. Imunon is a clinical-stage biotechnology company developing DNA-mediated immunotherapies and DNA vaccine technologies, and its filings offer detailed insight into clinical progress, capital structure and listing status.
Current reports on Form 8-K are central for tracking material events. Imunon uses 8-Ks to furnish press releases on quarterly financial results, announce conference calls and webcasts, describe capital markets transactions such as at-the-market equity offerings and registered direct offerings, and report stockholder meeting outcomes. Other 8-Ks document amendments to the Restated Certificate of Incorporation, including increases in authorized common stock and the implementation of a one-for-fifteen reverse stock split, as well as Nasdaq notices regarding minimum bid price and stockholders’ equity requirements and the subsequent confirmation of regained compliance.
Through 8-K items, investors can also follow how Imunon structures its financing, such as prospectus supplements filed under existing shelf registration statements on Form S-3 and the use of sales agents for ATM programs. These filings clarify the legal framework for share issuances and warrant exercises that affect outstanding equity.
Annual reports on Form 10-K and quarterly reports on Form 10-Q, when reviewed alongside 8-Ks, provide broader context on clinical programs like IMNN-001 and IMNN-101, risk factors, and research and development spending, although these specific forms are not reproduced in the excerpts here. For insider activity, Form 4 filings would show transactions by directors and officers, complementing the governance information disclosed in proxy-related materials.
On Stock Titan, Imunon filings are updated in near real time from EDGAR, and AI-powered summaries can help explain complex sections of 10-Ks, 10-Qs and 8-Ks in plain language. This allows investors to quickly understand how corporate actions, listing compliance steps and financing decisions intersect with the company’s clinical-stage biotechnology strategy.
Imunon, Inc. (IMNN) Form 4: Director Donald P. Braun reported two transactions dated 08/04/2025 following the company’s 1-for-15 reverse split completed 07/25/2025.
- Equity grant in lieu of cash fees: 2,040 common shares acquired at the split-adjusted closing price of $9.20, increasing Braun’s direct holdings to 3,747 shares.
- New stock option: right to purchase 250 shares at an exercise price of $9.20; 50% vests immediately, 25% after one year, and the remaining 25% after two years, expiring 08/04/2035.
Post-transaction, Braun also holds 250 options in addition to the common shares. The share acquisition represents payment of board fees in stock rather than cash, signalling alignment with shareholder interests, though the dollar value (<≈ $18.8 k) is modest relative to market capitalization. No sales were disclosed.